G-CSF treatment of healthy pediatric donors affects their hematopoietic microenvironment through changes in bone marrow plasma cytokines and stromal cells

Aerts‐Kaya, Fatima; Kılıç, Emine; Köse, Sevil; Aydın, Gülümser; Çağnan, Ilgın; Kuşkonmaz, Barış; Uçkan-Çetinkaya, Duygu

doi:10.1016/j.cyto.2020.155407

Cited by 5 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 A robust dose of exogenous G-CSF administration in murine models decreases niche factors, including CXCL12 and SCF, in the BM and induces migration of HSPCs from the BM into the blood. 38,39 Although the data on niche factors in the BM after G-CSF treatment in humans are limited, 40,41 we cannot completely rule out the possibility that G-CSF treatment for neutropenia in patients with PC might affect the levels of CXCL12 and SCF in the BM 28 days after CAR T-cell infusion.…”

Section: Discussionmentioning

confidence: 99%

Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy

et al. 2023

View full text Add to dashboard Cite

Summary Mechanisms of prolonged cytopenia (PC) after chimeric antigen receptor (CAR) T‐cell therapy, an emerging therapy for relapsed or refractory diffuse large B‐cell lymphoma, remain elusive. Haematopoiesis is tightly regulated by the bone marrow (BM) microenvironment, called the ‘niche’. To investigate whether alterations in the BM niche cells are associated with PC, we analysed CD271+ stromal cells in BM biopsy specimens and the cytokine profiles of the BM and serum obtained before and on day 28 after CAR T‐cell infusion. Imaging analyses of the BM biopsy specimens revealed that CD271+ niche cells were severely impaired after CAR T‐cell infusion in patients with PC. Cytokine analyses after CAR T‐cell infusion showed that CXC chemokine ligand 12 and stem cell factor, niche factors essential for haematopoietic recovery, were significantly decreased in the BM of patients with PC, suggesting reduced niche cell function. The levels of inflammation‐related cytokines on day 28 after CAR T‐cell infusion were consistently high in the BM of patients with PC. Thus, we demonstrate for the first time that BM niche disruption and sustained elevation of inflammation‐related cytokines in the BM following CAR T‐cell infusion are associated with subsequent PC.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Cyclosporine, short-term methotrexate (15 mg/m 2 on day +1, then 10 mg/m 2 on days +3, +6, and +11 intravenous injection after migration), and mycophenolate mofetil was used for graft-versus-host disease (GVHD) prophylaxis and the duration of immunosuppression ranged from 3 to 12 months according to patient GVHD status. The donor recieved granulocyte colony-stimulating factor (G-CSF) to mobilize grafts from BM and peripheral blood (PB) cells as what mentioned before [ 21 ]. The modified Glucksberg criteria defined and graded the acute GVHD (aGVHD) [ [22] , [23] , [24] , [25] ].…”

Section: Methodsmentioning

confidence: 99%